Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepofarsen in Pediatric LCA10 (BRIGHTEN)
NCT04855045Phase 3Unknown
- Sponsor
- ProQR Therapeutics
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 7
01
Overview
A Phase 3 trial of sepofarsen in Leber congenital amaurosis (LCA), sponsored by ProQR Therapeutics. Status: unknown.
02
Drugs
sepofarsen
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT04855045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855045.